{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T02:45:27Z","timestamp":1771987527697,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Microenvironment"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s12307-015-0170-1","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T14:15:09Z","timestamp":1439216109000},"page":"75-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia"],"prefix":"10.1007","volume":"8","author":[{"given":"Christina","family":"Hart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Vogelhuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Klobuch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Ghibelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Foell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selim","family":"Corbacioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Rehe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Haegeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Herr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Reichle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,11]]},"reference":[{"key":"170_CR1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12307-014-0163-5","volume":"7","author":"P Paterlini-Br\u00e9chot","year":"2014","unstructured":"Paterlini-Br\u00e9chot P (2014) About seed and soil. Cancer Microenviron 7:91\u201393","journal-title":"Cancer Microenviron"},{"key":"170_CR2","first-page":"445","volume":"2","author":"J Remon","year":"2013","unstructured":"Remon J, Majem M (2013) EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non-small cell lung cancer: a clue to overcoming resistance. Trans Lung Cancer Res 2:445\u2013448","journal-title":"Trans Lung Cancer Res"},{"key":"170_CR3","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","volume":"150","author":"M Imielinski","year":"2012","unstructured":"Imielinski M, Berger AH, Hammerman PS et al (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150:1107\u20131120","journal-title":"Cell"},{"key":"170_CR4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1172\/JCI64745","volume":"123","author":"K Faber","year":"2013","unstructured":"Faber K, Bullinger L, Ragu C et al (2013) CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPAR\u03b3 signaling. J Clin Invest 123:299\u2013314","journal-title":"J Clin Invest"},{"key":"170_CR5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/jmedgenet-2011-100637","volume":"49","author":"C Hafner","year":"2012","unstructured":"Hafner C, Toll A, Gantner S et al (2012) Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet 49:249\u2013253","journal-title":"J Med Genet"},{"key":"170_CR6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309\u2013322","journal-title":"Cancer Cell"},{"key":"170_CR7","first-page":"3759","volume":"49","author":"F Kallinowski","year":"1989","unstructured":"Kallinowski F, Schlenger KH, Runkel S et al (1989) Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 49:3759\u20133764","journal-title":"Cancer Res"},{"key":"170_CR8","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1158\/0008-5472.CAN-11-0568","volume":"1","author":"SJ Pitteri","year":"2011","unstructured":"Pitteri SJ, Kelly-Spratt KS, Gurley KE et al (2011) Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res 1:5090\u20135100","journal-title":"Cancer Res"},{"key":"170_CR9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/978-90-481-9531-2_24","volume-title":"From molecular to modular tumor therapy","author":"A Bundscherer","year":"2010","unstructured":"Bundscherer A, Hafner C (2010) Breathing new life into old drugs: Indication discovery by systems directed therapy. In: Reichle A (ed) From molecular to modular tumor therapy. Springer, Berlin, pp 483\u2013503"},{"key":"170_CR10","first-page":"442","volume":"8","author":"P Pantziarka","year":"2014","unstructured":"Pantziarka P, Bouche G, Meheus L et al (2014) The repurposing drugs in oncology (ReDO) project. Ecancer Med Sci 8:442","journal-title":"Ecancer Med Sci"},{"issue":"11","key":"170_CR11","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/jcp.24601","volume":"229","author":"A Papi","year":"2014","unstructured":"Papi A, De Carolis S, Bertoni S et al (2014) PPAR\u03b3 and RXR ligands disrupt the inflammatory cross-talk in the hypoxic breast cancer stem cells niche. J Cell Physiol 229(11):1595\u20131606","journal-title":"J Cell Physiol"},{"key":"170_CR12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nri1748","volume":"6","author":"CK Glass","year":"2006","unstructured":"Glass CK, Ogawa S (2006) Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 6:44\u201355","journal-title":"Nat Rev Immunol"},{"key":"170_CR13","unstructured":"Molecular cross-talk between nuclear receptors and nuclear factor-kB. Beck IME, Haegeman G, De Bosscher KA. Reichle A (ed.) From molecular to modular tumor therapy. Springer, Berlin, 191\u2013242"},{"key":"170_CR14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-90-481-9531-2_11","volume-title":"From molecular to modular tumor therapy","author":"U Emmenegger","year":"2010","unstructured":"Emmenegger U, Chow A, Bocci G (2010) The biomodulatory capacities of low-dose metronomic chemotherapy: Complex modulation of the tumor microenvironment. In: Reichle A (ed) From molecular to modular tumor therapy. Springer, Berlin, pp 243\u2013262"},{"issue":"Suppl 1","key":"170_CR15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12307-009-0023-x","volume":"2","author":"A Reichle","year":"2009","unstructured":"Reichle A, Hildebrandt GC (2009) Principles of modular tumor therapy. Cancer Microenviron 2(Suppl 1):227\u2013237","journal-title":"Cancer Microenviron"},{"key":"170_CR16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12307-008-0012-5","volume":"1","author":"A Reichle","year":"2008","unstructured":"Reichle A, Vogt T (2008) Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron 1:159\u2013170","journal-title":"Cancer Microenviron"},{"key":"170_CR17","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.semcdb.2013.07.001","volume":"24","author":"MA Mendoza-Parra","year":"2013","unstructured":"Mendoza-Parra MA, Gronemeyer H (2013) Genome-wide studies of nuclear receptors in cell fate decisions. Semin Cell Dev Biol 24:706\u2013715","journal-title":"Semin Cell Dev Biol"},{"key":"170_CR18","doi-asserted-by":"crossref","unstructured":"Reichle A. Including rationalizations of tumor-associated normative notions in pathophysiologic considerations: Communication-theoretical implications. Reichle A (ed) Evolution-adjusted tumor pathophysiology. Springer, Berlin, 289\u2013299","DOI":"10.1007\/978-94-007-6866-6_16"},{"key":"170_CR19","doi-asserted-by":"crossref","unstructured":"Reichle A, Gerner C, Haegeman G (2013) Criticizable claims for the validity of communication acts in biological systems: Therapeutic implications in cancer. Reichle A (ed) Evolution-adjusted tumor pathophysiology. Springer, Berlin, 169\u2013187","DOI":"10.1007\/978-94-007-6866-6_11"},{"key":"170_CR20","first-page":"87","volume":"1","author":"A Reichle","year":"2007","unstructured":"Reichle A, Grassinger J, Bross K et al (2007) C-reactive protein in patients with metastatic clear cell renal carcinoma: an Important biomarker for tumor-associated Inflammation. Biomark Insights 1:87\u201398","journal-title":"Biomark Insights"},{"key":"170_CR21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00345-010-0567-x","volume":"28","author":"B Walter","year":"2010","unstructured":"Walter B, Rogenhofer S, Vogelhuber M et al (2010) Modular therapy approach in metastatic castration-refractory prostate cancer. World J Urol 28:745\u2013750","journal-title":"World J Urol"},{"key":"170_CR22","doi-asserted-by":"crossref","unstructured":"Vogelhuber M, Feyerabend S, Stenzl A, et al. (2014) Biomodulatory treatment of patients with castration-resistant prostate cancer: A phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfan. Cancer Microenviron","DOI":"10.1007\/s12307-014-0161-7"},{"key":"170_CR23","doi-asserted-by":"crossref","unstructured":"Reichle A, Hart C, Grube M et al. (2012) Anti-inflammatory, immuno-modulatory and angiostatic treatment as third-line therapy for multiple myeloma (MM)\u2014a combined treatment setting of lenalidomide with pioglitazone, dexamethasone and low-Dose treosulfan (phase I\/II) Blood (ASH Annual Meeting Abstracts) 120:5029","DOI":"10.1182\/blood.V120.21.5029.5029"},{"issue":"1","key":"170_CR24","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.3324\/haematol.2014.115055","volume":"100","author":"S Thomas","year":"2015","unstructured":"Thomas S, Schelker R, Klobuch S et al (2015) Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia. Haematologica 100(1):e4\u2013e6","journal-title":"Haematologica"},{"key":"170_CR25","author":"P Ugocsai","year":"2015","unstructured":"Ugocsai P, Wolff D, Menhart K (2015) Biomodulatory metronomic therapy induces PET negative remissionin chemo- and brentuximab-refractory Hodgkin disease. Br J Haematol. doi: 10.1111\/bjh.13480","journal-title":"Br J Haematol"},{"key":"170_CR26","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1365-2141.2004.05359.x","volume":"128","author":"A Reichle","year":"2005","unstructured":"Reichle A, Vogt T, Kunz-Schughart L et al (2005) Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans\u2019 cell histiocytosis of adults. Br J Haematol 128:730\u2013732","journal-title":"Br J Haematol"},{"key":"170_CR27","doi-asserted-by":"crossref","unstructured":"Reichle A, Vogelhuber M, Vogt T et al. (2013) Long-term results of combined modularized, immune-modulatory, angiostatic, and antiinflammatory therapy in systemically pre-treated multi-systems Langerhans cell histiocytosis. Reichle A (ed) Evolution-adjusted tumor pathophysiology. Springer, Berlin, 35\u201345","DOI":"10.1007\/978-94-007-6866-6_4"},{"key":"170_CR28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1593\/neo.07871","volume":"10","author":"JC Pahler","year":"2008","unstructured":"Pahler JC, Tazzyman S, Erez N et al (2008) Plasticity in tumor promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 10:329\u2013340","journal-title":"Neoplasia"},{"key":"170_CR29","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(06)70798-7","volume":"7","author":"T Vogt","year":"2006","unstructured":"Vogt T, Coras B, Hafner C et al (2006) Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes. Lancet Oncol 7:695\u2013697","journal-title":"Lancet Oncol"},{"key":"170_CR30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883\u2013892","journal-title":"N Engl J Med"},{"key":"170_CR31","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE et al (2013) Cancer genome landscapes. Science 339:1546\u20131558","journal-title":"Science"},{"key":"170_CR32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood.V85.2.433.433","volume":"85","author":"H Tilg","year":"1995","unstructured":"Tilg H, Vogel W, Dinarello CA (1995) Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans. Blood 85:433\u2013435","journal-title":"Blood"},{"key":"170_CR33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/bbrc.2001.5640","volume":"287","author":"K Inoue","year":"2001","unstructured":"Inoue K, Kawahito Y, Tsubouchi Y et al (2001) Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 287:727\u2013732","journal-title":"Biochem Biophys Res Commun"},{"key":"170_CR34","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4049\/jimmunol.181.2.1052","volume":"181","author":"SA Gerber","year":"2008","unstructured":"Gerber SA, Pober JS (2008) IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells. J Immunol 181:1052\u20131062","journal-title":"J Immunol"},{"key":"170_CR35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","volume":"26","author":"DR Berthold","year":"2008","unstructured":"Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242\u2013245","journal-title":"J Clin Oncol"},{"key":"170_CR36","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00277-014-2126-9","volume":"93","author":"L Pleyer","year":"2014","unstructured":"Pleyer L, Burgstaller S, Girschikofsky M et al (2014) Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol 93:1825\u20131838","journal-title":"Ann Hematol"},{"key":"170_CR37","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","volume":"120","author":"S Luatti","year":"2012","unstructured":"Luatti S, Castagnetti F, Marzocchi G et al (2012) Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 120:761\u2013767","journal-title":"Blood"},{"key":"170_CR38","doi-asserted-by":"crossref","unstructured":"Yeung WWS, Ho MKC, Wong YH (2010) Functional Impacts of Signal Integration: Regulation of inflammation-related transcription factors by heterotrimeric G proteins. Reichle A (ed) From molecular to modular tumor therapy. Springer, Berlin, 161\u2013189","DOI":"10.1007\/978-90-481-9531-2_9"},{"key":"170_CR39","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/0008-5472.CAN-13-2357-T","volume":"74","author":"V Almendro","year":"2014","unstructured":"Almendro V, Kim HJ, Cheng YK et al (2014) Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 74:1338\u20131348","journal-title":"Cancer Res"},{"key":"170_CR40","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883\u2013892","journal-title":"N Engl J Med"},{"key":"170_CR41","doi-asserted-by":"crossref","first-page":"8954","DOI":"10.1158\/0008-5472.CAN-07-6088","volume":"68","author":"S Yegnasubramanian","year":"2008","unstructured":"Yegnasubramanian S, Haffner MC, Zhang Y et al (2008) DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 68:8954\u20138967","journal-title":"Cancer Res"},{"key":"170_CR42","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.18632\/oncotarget.2998","volume":"5","author":"L Galluzzi","year":"2014","unstructured":"Galluzzi L, Vacchelli E, Bravo-San Pedro JM et al (2014) Classification of current anticancer immunotherapies. Oncotarget 5:12472\u201312508","journal-title":"Oncotarget"},{"key":"170_CR43","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1158\/0008-5472.CAN-10-2907","volume":"71","author":"M Tosolini","year":"2011","unstructured":"Tosolini M, Kirilovsky A, Mlecnik B et al (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71:1263\u20131271","journal-title":"Cancer Res"},{"key":"170_CR44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coi.2014.01.001","volume":"27","author":"NA Giraldo","year":"2014","unstructured":"Giraldo NA, Becht E, Remark R et al (2014) The immune contexture of primary and metastatic human tumours. Curr Opin Immunol 27:8\u201315","journal-title":"Curr Opin Immunol"},{"key":"170_CR45","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960\u20131964s","journal-title":"Science"},{"key":"170_CR46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372:311\u2013319","journal-title":"N Engl J Med"},{"key":"170_CR47","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","volume":"17","author":"NS Vasudev","year":"2014","unstructured":"Vasudev NS, Reynolds AR (2014) Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17:471\u2013494","journal-title":"Angiogenesis"},{"key":"170_CR48","doi-asserted-by":"crossref","unstructured":"Reichle A and Hildebrandt GC (2010) The comparative uncovering of tumor systems biology by modularly targeting tumor-associated inflammation. Reichle A (ed) From molecular to modular tumor therapy. Springer, Berlin, 287\u2013303","DOI":"10.1007\/978-90-481-9531-2_13"},{"key":"170_CR49","doi-asserted-by":"crossref","first-page":"450","DOI":"10.15252\/emmm.201404414","volume":"7","author":"N Khandelwal","year":"2015","unstructured":"Khandelwal N, Breinig M, Speck T et al (2015) A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. EMBO Mol Med 7:450\u2013463","journal-title":"EMBO Mol Med"},{"key":"170_CR50","volume-title":"Evolution adjusted tumor pathophysiology","year":"2013","unstructured":"Reichle A (ed) (2013) Evolution adjusted tumor pathophysiology. Springer, Berlin"},{"key":"170_CR51","doi-asserted-by":"crossref","unstructured":"Reichle A. Biomodulatory therapy approaches in renal clear cell carcinoma: A perspective (2013) Reichle A (ed) Evolution-adjusted tumor pathophysiology. Springer, Berlin, 91\u2013100","DOI":"10.1007\/978-94-007-6866-6_7"},{"key":"170_CR52","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/CMR.0b013e3282f1d2c8","volume":"17","author":"A Reichle","year":"2007","unstructured":"Reichle A, Vogt T, Coras B et al (2007) Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res 17:360\u2013364","journal-title":"Melanoma Res"},{"key":"170_CR53","first-page":"848645","volume":"2009","author":"S Meyer","year":"2009","unstructured":"Meyer S, Vogt T, Landthaler M (2009) Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. PPAR Res 2009:848645","journal-title":"PPAR Res"},{"key":"170_CR54","doi-asserted-by":"crossref","first-page":"e52695","DOI":"10.1371\/journal.pone.0052695","volume":"7","author":"U Krug","year":"2012","unstructured":"Krug U, Koschmieder A, Schwammbach D et al (2012) Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study. PLoS ONE 7:e52695","journal-title":"PLoS ONE"},{"key":"170_CR55","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/sj.leu.2403528","volume":"18","author":"RF Schlenk","year":"2004","unstructured":"Schlenk RF, Fr\u00f6hling S, Hartmann F et al (2004) Phase III study of all-trans retinoic acid in previously untreated patients 61\u00a0years or older with acute myeloid leukemia. Leukemia 18:1798\u20131803","journal-title":"Leukemia"},{"issue":"6761 Suppl","key":"170_CR56","doi-asserted-by":"crossref","first-page":"C47","DOI":"10.1038\/35011540","volume":"402","author":"LH Hartwell","year":"1999","unstructured":"Hartwell LH, Hopfield JJ, Leibler S et al (1999) From molecular to modular cell biology. Nature 402(6761 Suppl):C47\u2013C52","journal-title":"Nature"},{"key":"170_CR57","doi-asserted-by":"crossref","unstructured":"Reichle A, Hildebrandt GC (2010) Uncovering tumor systems biology by biomodulatory therapy strategies. Reichle A (ed) From molecular to modular tumor therapy. Springer, Berlin, 287\u2013303","DOI":"10.1007\/978-90-481-9531-2_23"},{"key":"170_CR58","doi-asserted-by":"crossref","unstructured":"Paulitschke V, Kunstfeld R, Gerner C. Secretome proteomics, a novel tool for biomarkers discovery and for guiding biomodulatory therapy approaches. Reichle A (ed) From molecular to modular tumor therapy. Springer, Berlin, 405\u2013431","DOI":"10.1007\/978-90-481-9531-2_21"}],"container-title":["Cancer Microenvironment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12307-015-0170-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12307-015-0170-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12307-015-0170-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T01:34:56Z","timestamp":1599442496000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12307-015-0170-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["170"],"URL":"https:\/\/doi.org\/10.1007\/s12307-015-0170-1","relation":{},"ISSN":["1875-2292","1875-2284"],"issn-type":[{"value":"1875-2292","type":"print"},{"value":"1875-2284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}